ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
Revolutionary ovarian cancer rapid test available Q4 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
The partners also aim to expand their work to Latin America for the first time
The company also raised Rs 270 crore investment from Temasek in 2019
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Subscribe To Our Newsletter & Stay Updated
